Joanne Langton, MD
Endocrinology, Diabetes & Metabolism · Morristown, TNNPI 1255375465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 894 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations.
Across 894 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Medtronic$2K
- Novo Nordisk$2K
- Abbott$1K
- AbbVie$756
- Sanofi-aventis U.S. LLC$740
- plus $6K from 33 others
What the payments were for
- Travel & lodging$1,2398%
- Food & beverage$14,73692%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 189 | $3,095 |
| Medtronic(2 entities) | 55 | $2,236 |
| Novo Nordisk | 119 | $2,026 |
| Abbott | 64 | $1,048 |
| AbbVie | 63 | $756 |
| Sanofi-aventis U.S. LLC | 44 | $740 |
| AstraZeneca(2 entities) | 35 | $649 |
| Dexcom, Inc. | 30 | $617 |
| Insulet Corporation | 36 | $603 |
| Boehringer Ingelheim | 32 | $510 |
| Xeris Pharmaceuticals, Inc. | 28 | $503 |
| Amgen(2 entities) | 24 | $432 |
| Corcept Therapeutics | 18 | $352 |
| Bayer | 13 | $227 |
| Novartis | 14 | $210 |
| Merck | 19 | $202 |
| Lifescan, Inc. | 11 | $187 |
| Mannkind Corporation | 15 | $183 |
| Amneal Pharmaceuticals LLC | 16 | $149 |
| Sequel Med Tech, LLC | 6 | $136 |
| Johnson & Johnson | 8 | $127 |
| Tandem Diabetes Care, Inc. | 6 | $124 |
| Currax Pharmaceuticals LLC | 7 | $103 |
| Zealand Pharma US, Inc. | 4 | $94 |
| Amarin Pharma, Inc. | 5 | $87 |
| Shire North American Group Inc | 5 | $84 |
| GSK | 5 | $81 |
| Clarus Therapeutics Inc. | 5 | $78 |
| Kyowa Kirin, Inc. | 3 | $64 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Bigfoot Biomedical Inc | 2 | $43 |
| OPKO Pharmaceuticals, LLC | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Cequr Corporation | 1 | $32 |
| Antares Pharma, Inc. | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Pfizer | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| GRT US Holding, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,209
How this compares
$15,996 in reported general payments places this provider in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 584 | $732,075 |
| MounjaroTirzepatide | 451 | $556,756 |
| JardianceEmpagliflozin | 375 | $385,985 |
| Tresiba Flextouch U-200Insulin Degludec | 149 | $285,586 |
| Humulin R U-500Insulin Regular, Human | 67 | $185,647 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 160 | $157,661 |
| Tresiba Flextouch U-100Insulin Degludec | 180 | $153,051 |
| TrulicityDulaglutide | 119 | $152,371 |
| GlyxambiEmpagliflozin/Linagliptin | 131 | $143,899 |
| JanuviaSitagliptin Phosphate | 102 | $113,405 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 100 | $101,705 |
| HumalogInsulin Lispro | 256 | $99,098 |
| NovologInsulin Aspart | 225 | $89,783 |
| Humalog Kwikpen U-200Insulin Lispro | 24 | $70,501 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $62,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $2,026 | $902,912880 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $3,095 | $823,440949 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr | $510 | $601,179571 claims |
| MerckJanuvia, Janumet, Janumet Xr | $202 | $145,495138 claims |
| AstraZenecaFarxiga | $649 | $43,73749 claims |
| AbbVieSynthroid, Linzess | $756 | $42,034318 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $740 | $26,12823 claims |
| Clarus Therapeutics Inc.Jatenzo | $78 | $23,04617 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $149 | $11,3661,503 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Morristown
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Lisa MyersGermantown$609K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
- David EscalanteJellico$326K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.